(43) International Publication Date 18 March 2004 (18.03.2004)

PCT

(10) International Publication Number WO 2004/021994 A3

(51) International Patent Classification⁷: A61K 38/16, 31/715, C07K 16/00

(21) International Application Number:

PCT/US2003/027841

(22) International Filing Date:

4 September 2003 (04.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/408,126

4 September 2002 (04.09.2002) US

- (71) Applicants (for all designated States except US):
 BIOPOLYMER ENGINEERING, INC. [US/US]; 3388
 Mike Collins Drive, Eagan, MN 55121 (US). UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION,
 INC. [US/US]; 2305 Third Street, Louisville, KY 40208
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): OSTROFF, Gary, R. [US/US]; 301 Bridle Path, Worcester, MA 01604 (US). ROSS, Gordon, D. [US/US]; 11739 Paramont Way, Prospect, KY 40059 (US).
- (74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box 9133, Concord, MA 01742-9133 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 12 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CANCER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES

(57) Abstract: The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.





INTERNATIONAL SEARCH REPORT

International application No.

	PC1/USU3/2/841	
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 38/16, 31/715; C07K 16/00 US CL : 514/8, 54; 530/387.2, 388.2, 388.8		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/8, 54; 530/387.2, 388.2, 388.8		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category * Citation of document, with indication, where a		
X Database HCAPLUS on STN (Columbus, OH, USA	A), No. 137:119657, CHEUNG, N., 1-2, 4, 11-15	
"Antitumor antibody-enhancing glucan," WO200200 Y entire abstract.	58711 A1, 01 August 2002, abstract, see 3, 5-10, 16-18	
•		
Further documents are listed in the continuation of Box C.	See patent family annex.	
Special categories of cited documents:	"T" later document published after the international filing date or priority	
"A" document defining the general state of the art which is not considered to be of particular relevance	date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is	
"O" document referring to an oral disclosure, use, exhibition or other means	combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"P" document published prior to the international filing date but later than the priority date claimed .	"&" document member of the same patent family	
Date of the actual completion of the international search	Date of mailing of the international search report	
10 June 2004 (10.06.2004)	21 JUN 2004	
Name and mailing address of the ISA/US	Authorized officer Repecca Con Manufacture General Control of Con	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450		
Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Telephone No. 703-308-1235	

	PCT/US03/27841
INTERNATIONAL SEARCH REPORT	FC1/0503/2/841
INTERNATIONAL SEARCH REPORT	
·	
Continuation of D. MICH DC CEAN CONTINUE.	
Continuation of B. FIELDS SEARCHED Item 3:	
REGISTRY, CAPLUS, EMBASE, MEDLINE BIOSIS, DRUGU, IPA, WPIDS; gagents, antibodies, complement.	ducan, trastuzumab, rituximab, cetuximab, antigumor
	í
	•
Form PCT/ISA/210 (second sheet) (July 1998)	